Non-Hodgkin’s Lymphoma in Patients With Advanced HIV Infection Treated With Zidovudine

Richard D. Moore, Harold Kessler, Douglas D. Richman, Charles Flexner, Richard E. Chaisson

Research output: Contribution to journalArticlepeer-review


We wished to determine the incidence of human immunodeficiency virus—related high-grade non-Hodgkin’s lymphoma (NHL) and identify factors associated with the development of NHL in patients receiving zidovudine. Data are from a 2-year prospective, observational, multisite study of 1030 patients with the acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex who received zidovudine. Non-Hodgkin’s lymphoma developed in 24 (2.3%) of 1030 patients who received zidovudine during 1463 person-years of follow-up (rate, 1.6 per 100 person-years of therapy). The relative hazard for development of NHL was stable throughout 2 years of therapy, with the risk of developing NHL 0.8% for each additional 6 months of therapy. Factors associated with development of NHL were a prior diagnosis of Kaposi’s sarcoma, herpes simplex virus infection, or lower mean neutrophil count. Less strongly associated was a prior diagnosis of oral hairy leukoplakia or homosexual transmission of HIV. By Cox proportional hazards analysis, a prior diagnosis of Kaposi’s sarcoma, cytomegalovirus disease, or oral hairy leukoplakia was most strongly associated with development of NHL. Our study demonstrates a relatively high incidence of NHL in patients with advanced human immunodeficiency virus disease who are undergoing antiretroviral therapy and suggests possible risk factors for development of NHL.

Original languageEnglish (US)
Pages (from-to)2208-2211
Number of pages4
JournalJAMA: The Journal of the American Medical Association
Issue number17
StatePublished - May 1 1991

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Non-Hodgkin’s Lymphoma in Patients With Advanced HIV Infection Treated With Zidovudine'. Together they form a unique fingerprint.

Cite this